{
    "nct_id": "NCT03259074",
    "official_title": "A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis",
    "inclusion_criteria": "* Male or non-pregnant, non-nursing female patients at least 18 years of age\n* Diagnosis of moderate to severe Ankylosing Spondylitis with radiologic evidence (centrally read X-ray) fulfilling the Modified New York criteria for AS despite previous or current NSAID/ nonbiologic DMARD therapy\n* Active AS assessed by total BASDAI ≥ 4 on a scale of 0-10\n* Spinal pain as measured by BASDAI question #2 ≥ 4 (0-10)\n* Total back pain as measured by visual analog scale (VAS) ≥ 40 mm (0-100 mm)\n* hsCRP ≥ 5 mg/L OR presence of at least 1 syndesmophyte on centrally read spinal X-ray\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with total ankylosis of the spine\n* Pregnant or nursing (lactating) women\n* Evidence of ongoing infectious or malignant process\n* Previous exposure to any biologic immunomodulating agent, including those targeting IL-17, IL-17 receptor or TNFα\n* Subjects taking high potency opioid analgesics\n* Previous treatment with any cell-depleting therapies including but not limited to anti-CD20, investigational agents\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": ""
}